keyword
MENU ▼
Read by QxMD icon Read
search

adalimumab level

keyword
https://www.readbyqxmd.com/read/28632883/importance-of-immunogenicity-testing-for-cost-effective-management-of-psoriasis-patients-treated-with-adalimumab
#1
Fernando Mota, Esmeralda Neves, José Carlos Oliveira, Manuela Selores, Tiago Torres
INTRODUCTION: Up to 30% of patients treated with anti-tumor necrosis factor drugs do not respond adequately, and up to 50% lose response over time. Immunogenicity is now known to be one of the main causes of this loss of response. METHODS: Serum levels of adalimumab and anti-drug antibodies (ADAs) were measured in 19 patients with psoriasis. RESULTS: Eighty-nine percent of the patients were responders (Psoriasis Area Severity Index (PASI) > 75) and 11% were partial responders (PASI 50-75)...
June 2017: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
https://www.readbyqxmd.com/read/28604144/anti-tnf-%C3%AE-effects-on-anemia-in-rheumatoid-and-psoriatic-arthritis
#2
Addolorata Corrado, Valeria Di Bello, Francesca d'Onofrio, Nicola Maruotti, Francesco Paolo Cantatore
A key role in the pathogenesis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is played by inflammatory cytokines, including tumor necrosis factor-α (TNF-α), which are also involved in inducing inflammatory anemia. We have followed 67 RA patients and 64 PsA patients for 1 year to evaluate the effects of TNF-α inhibitors on disease activity and on inflammatory anemia. Patients were divided into three different treatment groups, according to a randomized assignment to receive therapy with etanercept, adalimumab, or infliximab...
June 1, 2017: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/28604127/correlation-between-trough-serum-levels-of-adalimumab-and-absolute-pasi-score-in-a-series-of-patients-with-psoriasis
#3
J M Carrascosa Carrilllo, M Toro Montecinos, F Ballescá López, A Teniente Serra, E Martínez Cáceres, C Ferrándiz
BACKGROUND: The possibility of monitoring serum drug levels has opened the door to optimizing biologic therapy. To consolidate this advance, it is imperative to demonstrate an adequate correlation between serum drug levels and clinical course. OBJECTIVES: To investigate whether a correlation exists between adalimumab levels and clinical response measured as absolute PASI. METHODS: In a prospective cohort study, we enrolled 51 patients with psoriasis treated with adalimumab for at least 16 weeks...
June 12, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28598681/soluble-cd206-plasma-levels-in-rheumatoid-arthritis-reflect-decrease-in-disease-activity
#4
Line Dam Heftdal, Kristian Stengaard-Pedersen, Lykke Midtbøll Ørnbjerg, Merete Lund Hetland, Kim Hørslev-Petersen, Peter Junker, Mikkel Østergaard, Malene Hvid, Bent Deleuran, Holger Jon Møller, Stinne Ravn Greisen
Rheumatoid arthritis (RA) is characterized by chronic joint inflammation and infiltration by activated macrophages. TNFα is a central mediator in this process. The mannose receptor, CD206, is a scavenger receptor expressed by M2A-macrophages and dendritic cells. It is involved in collagen internalization and degradation. The soluble form has been suggested as a biomarker of M2A-macrophage activation. The aim of this study was to investigate sCD206 plasma levels in early RA patients initiating anti-TNFα treatment...
June 9, 2017: Scandinavian Journal of Clinical and Laboratory Investigation
https://www.readbyqxmd.com/read/28560470/cost-per-response-for-abatacept-versus-adalimumab-in-rheumatoid-arthritis-by-acpa-subgroups-in-germany-italy-spain-us-and-canada
#5
Laure Weijers, Christoph Baerwald, Francesco S Mennini, José M Rodríguez-Heredia, Martin J Bergman, Denis Choquette, Kirsten H Herrmann, Giulia Attinà, Carmela Nappi, Silvia Jimenez Merino, Chad Patel, Mondher Mtibaa, Jason Foo
Rheumatoid arthritis (RA) is a chronic inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses a significant economic burden. The Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Subjects with Background Methotrexate (AMPLE) trial was a head-to-head, randomized study comparing abatacept in serum anti-citrullinated protein antibody (ACPA)-positive patients, with increasing efficacy across ACPA quartile levels. The aim of this study was to evaluate the cost per response accrued using abatacept versus adalimumab in ACPA-positive and ACPA-negative patients with RA from the health care perspective in Germany, Italy, Spain, the US and Canada...
May 30, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28557009/drug-concentration-and-antidrug-antibodies-in-patients-with-psoriasis-treated-with-adalimumab-or-etanercept
#6
Mette Gyldenløve, Claus Zachariae, Peter Jensen, Helena Griehsel, Mona Ståhle, Lone Skov
Tumour necrosis factor (TNF)-α antagonists are used for treatment of psoriasis and are generally effective and well tolerated (1,2). However, a substantial proportion of patients lose effect over time. The underlying mechanisms are unclear, but data suggest that formation of anti-drug antibodies leads to sub-therapeutic drug levels and thereby loss of efficacy (3). This article is protected by copyright. All rights reserved.
May 30, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28537934/alternative-treatments-for-chronic-spontaneous-urticaria-beyond-the-guideline-algorithm
#7
Gino A Vena, Marcus Maurer, Nicoletta Cassano, Torsten Zuberbier
PURPOSE OF REVIEW: The international EAACI/GALEN/EDF/WAO guideline suggests a stepwise approach for the therapeutic management of chronic spontaneous urticaria (CSU), outlined in an algorithm. The aim of this article is to summarize and review the evidence available on alternative treatment options for CSU outside of this algorithm. RECENT FINDINGS: Although CSU is a common disease, there are a limited number of high-quality studies, and only antihistamines and omalizumab are licensed for its treatment...
May 22, 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28522947/clinical-efficacy-of-adalimumab-versus-infliximab-and-the-factors-associated-with-recurrence-or-aggravation-during-treatment-of-anal-fistulas-in-crohn-s-disease
#8
Cheng-Chun Ji, Shota Takano
BACKGROUND/AIMS: Infliximab has proven to be effective in the treatment of perianal fistulas in Crohn's disease (CD) but the efficacy of adalimumab is still unclear. The aim of this study is to assess the clinical efficacy of adalimumab and compare the results with those for infliximab. METHODS: Forty-seven CD patients treated for perianal fistulas with infliximab from September 2005 to December 2010 (n=31), or with adalimumab from November 2010 to May 2012 (n=16), were enrolled in this retrospective study...
April 2017: Intestinal Research
https://www.readbyqxmd.com/read/28504555/frequency-and-characteristics-of-infusion-reactions-during-biosimilar-infliximab-treatment-in-inflammatory-bowel-diseases-results-from-central-european-nationwide-cohort
#9
Anita Bálint, Mariann Rutka, Zsuzsanna Végh, Zsuzsanna Kürti, Krisztina B Gecse, János Banai, László Bene, Beáta Gasztonyi, Tünde Kristóf, László Lakatos, Pál Miheller, Károly Palatka, Árpád Patai, Ágnes Salamon, Tamás Szamosi, Zoltán Szepes, Gábor Tamás Tóth, Áron Vincze, Renáta Bor, Ágnes Milassin, Anna Fábián, Ferenc Nagy, Martin Kolar, Martin Bortlik, Dana Duricova, Veronika Hruba, Martin Lukas, Katarina Mitrova, Karin Malickova, Milan Lukas, Péter L Lakatos, Tamás Molnár, Klaudia Farkas
BACKGROUND: Safety data of the 'real life' use of an infliximab biosimilar, CT-P13 in inflammatory bowel disease (IBD) are still lacking. Our aim was to assess the frequency and characteristics of infusion reactions during CT-P13 therapy in 13 Hungarian and 1 Czech IBD centres. METHODS: Clinical and safety data was registered at fixed appointments. Trough levels and anti-drug antibody (ADA) concentration were measured by ELISA. Association between demographic, clinical, laboratory parameters and infusion reaction rates were evaluated statistically...
May 26, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28493493/neutrophil-lymphocyte-ratio-platelet-lymphocyte-ratio-and-mean-platelet-volume-in-japanese-patients-with-psoriasis-and-psoriatic-arthritis-response-to-therapy-with-biologics
#10
Akihiko Asahina, Naoko Kubo, Yoshinori Umezawa, Hiromi Honda, Koichi Yanaba, Hidemi Nakagawa
Recent studies indicate the presence of systemic inflammation in psoriatic patients, and this inflammatory status is significantly associated with a range of comorbidities. The aim of this study was to evaluate the clinical significance of novel inflammatory biomarkers, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and mean platelet volume (MPV) in Japanese patients with plaque-type psoriasis (PsV) and psoriatic arthritis (PsA). One hundred and eighty-six patients with PsV and 50 patients with PsA treated with biologics, including infliximab, adalimumab and ustekinumab, were retrospectively analyzed before and after treatment...
May 11, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28489469/significant-se-selectin-levels-reduction-after-6-months-of-anti-tnf-%C3%AE-therapy-in-non-diabetic-patients-with-moderate-to-severe-psoriasis
#11
Fernanda Genre, Susana Armesto, Alfonso Corrales, Raquel López-Mejías, Sara Remuzgo-Martínez, Trinitario Pina, Begoña Ubilla, Verónica Mijares, José Luis Martín-Varillas, Javier Rueda-Gotor, Virginia Portilla, Trinidad Dierssen-Sotos, Marcos Antonio González-López, María Del Carmen González-Vela, Ricardo Blanco, Javier Llorca, José Luis Hernández, Miguel Ángel González-Gay
PURPOSE: Psoriasis patients have high risk of atherosclerosis, characterized by endothelial dysfunction. We aimed to study the association of the endothelial activation biomarkers monocyte chemoattractant protein 1 (MCP-1), soluble (s) E-selectin and P-selectin with disease activity and severity in psoriasis patients treated with anti-TNF-α therapy. Also, to evaluate the relationship of metabolic syndrome features with these biomarkers and the effect of anti-TNF-α therapy on these molecules...
May 31, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28486256/one-year-clinical-outcomes-in-an-ibd-cohort-who-have-previously-had-anti-tnfa-trough-and-antibody-levels-assessed
#12
Donal Tighe, Barry Hall, Shivashini Kirthi Jeyarajah, Sinead Smith, Niall Breslin, Barbara Ryan, Deirdre McNamara
BACKGROUND: Loss of response (LOR) is a big concern for anti-TNFa therapies in inflammatory bowel disease. Immunomonitoring may be useful to optimize response rates and overcome secondary LOR. METHODS: This was an observational retrospective cohort study of a group of patients with inflammatory bowel disease on infliximab (IFX) and adalimumab (ADA) who had anti-TNFa trough and antibody levels measured, during maintenance phase of treatment. Anti-TNFa trough and antibody levels were measured using standard enzyme-linked immunosorbent assay techniques...
July 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28483767/incidence-and-prevalence-of-psoriatic-arthritis-in-denmark-a-nationwide-register-linkage-study
#13
Alexander Egeberg, Lars Erik Kristensen, Jacob P Thyssen, Gunnar Hilmar Gislason, Alice B Gottlieb, Laura C Coates, Denis Jullien, Paolo Gisondi, Dafna D Gladman, Lone Skov, Lotus Mallbris
OBJECTIVES: To examine the incidence and temporal trends of psoriatic arthritis (PsA) in the general population in Denmark. METHODS: Using nationwide registry data, we estimated the number of patients with incident PsA within each 1-year period between 1997 and 2011 and calculated the rate of PsA cases within gender and age subgroups. Incidence rates were presented per 100 000 person-years. RESULTS: There was a female predominance ranging from 50...
May 8, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28482738/hepcidin-plasma-levels-are-not-associated-with-changes-in-haemoglobin-in-early-rheumatoid-arthritis-patients
#14
R D Østgård, H Glerup, A G Jurik, T W Kragstrup, K Stengaard-Pedersen, M L Hetland, K Hørslev-Petersen, P Junker, B W Deleuran
OBJECTIVE: A reduction in haemoglobin level is a frequent complication among rheumatoid arthritis (RA) patients. Hepcidin has been linked to disturbed erythropoiesis. The objective of this study was to investigate the longitudinal changes in hepcidin in patients with early RA. METHOD: Hepcidin plasma concentrations were measured by enzyme-linked immunosorbent assay in patients with early RA (n = 80) and healthy volunteers (HV, n = 40). Haemoglobin and other iron-related proteins were also measured...
May 9, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28481014/infliximab-and-adalimumab-drug-levels-in-crohn-s-disease-contrasting-associations-with-disease-activity-and-influencing-factors
#15
M G Ward, B Warner, N Unsworth, S-W Chuah, C Brownclarke, S Shieh, M Parkes, J D Sanderson, Z Arkir, J Reynolds, P R Gibson, P M Irving
BACKGROUND: Discriminative drug level thresholds for disease activity endpoints in patients with Crohn's disease. have been consistently demonstrated with infliximab, but not adalimumab. AIMS: To identify threshold concentrations for infliximab and adalimumab in Crohn's disease according to different disease endpoints, and factors that influence drug levels. METHODS: We performed a cross-sectional service evaluation of patients receiving maintenance infliximab or adalimumab for Crohn's disease...
May 8, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28463029/high-rate-of-improvement-in-serum-matrix-metalloproteinase-3-levels-at-4-weeks-predicts-remission-at-52-weeks-in-ra-patients-treated-with-adalimumab
#16
Yosuke Hattori, Toshihisa Kojima, Atsushi Kaneko, Daihei Kida, Yuji Hirano, Takayoshi Fujibayashi, Yuichiro Yabe, Takeshi Oguchi, Yasuhide Kanayama, Hiroyuki Miyake, Takefumi Kato, Hideki Takagi, Masatoshi Hayashi, Takayasu Ito, Tomone Shioura, Nobunori Takahashi, Hisato Ishikawa, Koji Funahashi, Naoki Ishiguro
OBJECTIVE: This study aimed to determine whether serum matrix metalloproteinase-3 (MMP-3) levels can predict remission in rheumatoid arthritis (RA) patients treated with adalimumab (ADA). METHODS: Subjects were 114 RA patients continuously treated with ADA for 52 weeks. Predictive factors at baseline and 4 weeks after initiation of ADA therapy for the achievement of remission (28-point count Disease Activity Score-CRP (DAS28-CRP) < 2.3) at 52 weeks were evaluated by multivariate logistic regression analysis...
May 2, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28460083/estimated-medical-expenditure-and-risk-of-job-loss-among-rheumatoid-arthritis-patients-undergoing-tofacitinib-treatment-post-hoc-analyses-of-two-randomized-clinical-trials
#17
Regina Rendas-Baum, Mark Kosinski, Amitabh Singh, Charles A Mebus, Bethany E Wilkinson, Gene V Wallenstein
Objectives.: RA causes high disability levels and reduces health-related quality of life, triggering increased costs and risk of unemployment. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. These post hoc analyses of phase 3 data aimed to assess monthly medical expenditure (MME) and risk of job loss for tofacitinib treatment vs placebo. Methods.: Data analysed were from two randomized phase 3 studies of RA patients (n = 1115) with inadequate response to MTX or TNF inhibitors (TNFi) receiving tofacitinib 5 or 10 mg twice daily, adalimumab (one study only) or placebo, in combination with MTX...
April 28, 2017: Rheumatology
https://www.readbyqxmd.com/read/28448562/the-impact-of-anti-drug-antibodies-on-drug-concentrations-and-clinical-outcomes-in-rheumatoid-arthritis-patients-treated-with-adalimumab-etanercept-or-infliximab-results-from-a-multinational-real-world-clinical-practice-non-interventional-study
#18
Robert J Moots, Ricardo M Xavier, Chi Chiu Mok, Mahboob U Rahman, Wen-Chan Tsai, Mustafa H Al-Maini, Karel Pavelka, Ehab Mahgoub, Sameer Kotak, Joan Korth-Bradley, Ron Pedersen, Linda Mele, Qi Shen, Bonnie Vlahos
OBJECTIVE: To assess the incidence of anti-drug antibodies (ADA) in patients with rheumatoid arthritis (RA) treated with the TNF inhibitors etanercept (ETN), adalimumab (ADL), or infliximab (IFX), and determine the potential relationship with trough drug concentration, efficacy, and patient-reported outcomes. METHODS: This multi-national, non-interventional, cross-sectional study (NCT01981473) enrolled adult patients with RA treated continuously for 6-24 months with ETN, ADL, or IFX...
2017: PloS One
https://www.readbyqxmd.com/read/28425772/prediction-of-successful-dose-reduction-or-discontinuation-of-adalimumab-etanercept-or-infliximab-in-rheumatoid-arthritis-patients-using-serum-drug-levels-and-antidrug-antibody-measurement
#19
RANDOMIZED CONTROLLED TRIAL
Cam Bouman, N van Herwaarden, Fhj van den Hoogen, A van der Maas, Bjf van den Bemt, A A den Broeder
BACKGROUND: To evaluate if TNF inhibitor serum drug levels (DL) or anti-drug antibodies (ADAb) can predict successful dose reduction (in patients with high DL) or discontinuation (in patients with no/low DL or ADAb) in rheumatoid arthritis (RA) patients. RESEARCH DESIGN AND METHODS: RA patients that were using adalimumab (n = 42), etanercept (n = 76) or infliximab (n = 51) and were doing well, were tapered until discontinuation or flare (1-1.5 year follow up)...
June 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28417141/incidence-and-prevalence-of-psoriasis-in-denmark
#20
Alexander Egeberg, Lone Skov, Gunnar H Gislason, Jacob P Thyssen, Lotus Mallbris
The incidence and temporal trends of psoriasis in Denmark between 2003 and 2012 were examined. There was a female predominance ranging between 50.0% (2007) and 55.4% (2009), and the mean age at time of diagnosis was 47.7-58.7 years. A total of 126,055 patients with psoriasis (prevalence 2.2%) were identified. Incidence rates of psoriasis (per 100,000 person years) ranged from 107.5 in 2005 to a peak incidence of 199.5 in 2010. Incidence rates were higher for women, and patients aged 60-69 years, respectively...
April 18, 2017: Acta Dermato-venereologica
keyword
keyword
53794
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"